Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025

BridgeBio shares promising data from muscular dystrophy drug trial

The California-based biotech announced positive results from their latest limb-girdle muscular dystrophy type 2i (LGMD2i) program trials, linking their drug, BBP-418, to positive biomarker changes and functional endpoints in the right direction.

LGMD2i is a rare form of muscular dystrophy caused by mutations in the FKRP gene, for which there are currently no approved treatment options. Mutations in the gene impair the addition of a specific sugar molecule to a protein that acts as a molecular ‘shock absorber’ in cells and normally helps prevent damage from everyday muscle use. BBP-418, also called ribitol, is said to work by catalyzing the enzyme to function again, increasing sugar-protein interactions, and theoretically enabling muscle cells to repair themselves.

The phase 2 study included 14 patients with LGMD2i, and BridgeBio tested ascending doses of the drug candidate in 3 different cohorts, assessing participants after 90 and 180 days.

Among the promising results, BridgeBio reported a 43% increase in the ratio of these sugar-protein interactions; an average of 70% reduction in the levels of creatine kinase, a marker of muscle breakdown; and an increase in walking velocity.

“The positive results from the Phase 2 study exceed expectations and are incredibly exciting as they demonstrate consistent improvements in key markers of muscle function and support further study,” concluded Amy Harper, primary investigator of the trial.

Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025